Alexander T. Falk

ORCID: 0000-0003-3915-2346
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Colorectal and Anal Carcinomas
  • Advanced Radiotherapy Techniques
  • Prostate Cancer Treatment and Research
  • Prostate Cancer Diagnosis and Treatment
  • Sarcoma Diagnosis and Treatment
  • Colorectal Cancer Surgical Treatments
  • Lung Cancer Treatments and Mutations
  • Breast Cancer Treatment Studies
  • Management of metastatic bone disease
  • Cancer Diagnosis and Treatment
  • Radiopharmaceutical Chemistry and Applications
  • Head and Neck Cancer Studies
  • Glioma Diagnosis and Treatment
  • Brain Metastases and Treatment
  • Gastric Cancer Management and Outcomes
  • Urologic and reproductive health conditions
  • Cancer Immunotherapy and Biomarkers
  • Cancer Genomics and Diagnostics
  • Endometrial and Cervical Cancer Treatments
  • Occupational and environmental lung diseases
  • Vascular Tumors and Angiosarcomas
  • Cholangiocarcinoma and Gallbladder Cancer Studies
  • Lung Cancer Research Studies
  • Radiation Dose and Imaging
  • Oral health in cancer treatment

Krankenhaus Porz am Rhein
2023

Centre Azuréen de Cancérologie
2020-2023

Centre Antoine Lacassagne
2012-2021

Institut Arnault Tzanck
2020

Université Côte d'Azur
2012-2018

Fondation ARC pour la Recherche sur le Cancer
2018

Institut de Cancérologie de Lorraine
2018

Observatoire de la Côte d’Azur
2018

Centre National de la Recherche Scientifique
2016-2017

Inserm
2016-2017

Technetium-99m, the most commonly used radionuclide in nuclear medicine, can be attached to biologically important molecules through a variety of chelating agents, choice which depends upon imaging application. The prostate-specific membrane antigen (PSMA) is increasingly recognized as an target for and therapy prostate cancer (PCa). Three different (99m)Tc-labeling methods were employed investigate effect chelator on biodistribution PCa tumor uptake profiles 12 new urea-based PSMA-targeted...

10.1021/jm400823w article EN Journal of Medicinal Chemistry 2013-06-25

To assess clinical outcomes of high-dose rate interstitial brachytherapy (HIB) in localized penile carcinoma. From 03/2006 to 08/2013, patients with biopsy-proven T1-T2 (<4 cm) non-metastatic squamous cell carcinoma underwent HIB. Under general anaesthesia, after Foley catheter placement, needles were placed the target volume using a dedicated template. Planification was carried out post-implant CT-scan deliver total dose 36 Gy 9 fractions over 5 days (in adjuvant setting) or 39 (as...

10.1186/1748-717x-9-142 article EN cc-by Radiation Oncology 2014-06-19

BACKGROUND: Because of the rarity condition, studies concerning management patients with squamous cell carcinoma anus distant metastasis are scarce. The available indicate poor outcomes exclusive chemotherapy. OBJECTIVE: Our aim was to evaluate impact multidisciplinary treatment on overall survival among presenting metastatic anus. DESIGN: This a retrospective study. SETTINGS: study conducted at single French institution between 2000 and 2014. PATIENTS: Consecutive histologically proven,...

10.1097/dcr.0000000000000827 article EN Diseases of the Colon & Rectum 2017-07-06

To assess clinical outcomes of patients treated with a high-dose rate brachytherapy boost for anal canal cancer (ACC). From August 2005 to February 2013, 28 presenting an ACC by split-course external beam radiotherapy (EBRT) and HDR or without chemotherapy in French regional center Nice were retrospectively analyzed. Median age was 60.6 years [34 - 83], 25 presented squamous cell carcinoma 3 adenocarcinoma; 21 received chemotherapy. dose EBRT 45 Gy [43.2 52]. 12 [10 15] median duration 2...

10.1186/s13014-014-0240-4 article EN cc-by Radiation Oncology 2014-11-05

There is no consensus for parametrial boost technic while both transvaginal and transperineal approaches are discussed. A prototype was developed consisting of a perineal template, allowing needle insertion. This study analyzed acute toxicity concomitant cervical high-dose-rate brachytherapy (HDRB) locally advanced cancer.From 01.2011 to 12.2014, 33 patients (pts) presenting cancer with invasion were treated. After the first course external beam radiation therapy cisplatinum, HDRB performed...

10.5114/jcb.2016.57535 article EN cc-by-nc-sa Journal of Contemporary Brachytherapy 2016-01-01

Ziel: Analyse akuter zerebraler Ischämiebefunde in der Perfusions-CT bei unterschiedlicher Parameterdarstellung und Beurteilung ihrer Wertigkeit im Vergleich zur Nativ-CT. Methode: von Nativ-CT-Aufnahmen 45 Patienten mit Ischämie (< 6 Stunden) bezüglich des Vorliegens CT-Frühzeichen Ischämieausdehnung Abhängigkeit vom lschämiegrad. Ergebnisse: Bei 75 % aller erfolgte die CT-Untersuchung innerhalb 2 Stunden nach Symptombeginn. 29 wiesen ischämische Frühzeichen Nativ-CT auf, alle hatten einen...

10.1055/s-2000-120 article DE RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren 2000-03-01
Coming Soon ...